Stent Remains Available Despite Trial Showing Dangers
A leading critic says that the FDA has been remiss for not removing a stent from the market although strong evidence exists that its use leads to more deaths and strokes.
…
Now, in a paper published in BMJ, a group of physicians led by Rita Redberg say that by not removing Wingspan from the market the FDA is shirking its “responsibility to protect the public’s health.”
…
Categories: Profile
Comments (0)
Trackbacks (0)
Leave a comment
Trackback
Collateral Damage: A Patient, a New Procedure and the Learning Curve
"Riveting!"
Profiles in Medical Ethics 